Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

scientific article published on 04 March 2016

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOTARGET.7914
P932PMC publication ID4991440
P698PubMed publication ID26956050

P50authorLewis R. RobertsQ38601327
P2093author name stringYing Li
Gang Chen
Charles D Smith
Xiaoping Zou
Frank A Sinicrope
Roongruedee Chaiteerakij
Catherine D Moser
Melanie B Thomas
Yanling Zhou
Xiwei Ding
Albert Ndzengue
Shengbing Huang
Jeffrey Boakye
Hassan Shaleh
P2860cites workDrug combination studies and their synergy quantification using the Chou-Talalay methodQ29617422
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Q30408885
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingQ33752594
Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2Q33755206
A novel sphingosine kinase inhibitor induces autophagy in tumor cellsQ33861997
Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinomaQ33925154
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.Q33936548
Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.Q34079007
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Q34209320
SPHK1 regulates proliferation and survival responses in triple-negative breast cancerQ34227524
Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.Q34251293
Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinaseQ34310422
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinomaQ34536227
Pathogenesis, diagnosis, and management of cholangiocarcinomaQ34656747
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2Q34891145
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenograftsQ34928923
Combined anticancer effects of sphingosine kinase inhibitors and sorafenibQ34949678
ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancerQ36216032
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencingQ36388792
Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.Q36414244
Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.Q36627430
Biliary tract cancers in Olmsted County, Minnesota, 1976-2008.Q36846561
The role of autophagy in cancer: therapeutic implicationsQ37924056
Sphingosine 1-phosphate signalling in cancerQ37977171
Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survivalQ38424345
Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survivalQ38987627
Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.Q39097511
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.Q39222582
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer modelsQ39242149
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cellsQ39589946
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotypeQ39823174
Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patientsQ39881982
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cellsQ40345898
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progressionQ40423379
Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell linesQ41464352
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinomaQ42045560
Autophagy in intra-hepatic cholangiocarcinomaQ42080884
Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosisQ42799996
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.Q44503780
Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.Q53090136
Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.Q54363475
Incidence and mortality trends for biliary tract cancers in Austria.Q54774218
P433issue15
P407language of work or nameEnglishQ1860
P921main subjectautophagyQ288322
cholangiocarcinomaQ124292
P304page(s)20080-20092
P577publication date2016-04-01
P1433published inOncotargetQ1573155
P1476titleAntitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells
P478volume7

Reverse relations

described by source (P1343)
Q54832088EGI-1
Q54896725HuCC-T1
Q54896845HuH-28
Q116049708LIV27
Q54937185OZ
Q54953627SK-ChA-1

cites work (P2860)
Q55001442A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
Q61818544Diverse Functions of Autophagy in Liver Physiology and Liver Diseases
Q42972395Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells
Q37690896Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin
Q90072359Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives
Q56387433Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era
Q41521563SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models
Q45072762Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.
Q28069459Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment
Q97073430Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG)
Q90642085Targeting Sphingosine Kinases for the Treatment of Cancer
Q64072869Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma
Q47130227The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer.
Q48349932The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
Q58804941Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy

Search more.